Treatment with multi kinase inhibitor sorafenib and xenobiotic-processing enzyme inhibitor sulforaphane could reduce the ALDH1 activity in pancreatic cancer cells and consequently, inhibit tumor growth inhibition in vivo, indicating the potential for a CSC-targeting therapeutic strategy [135]. The gene discussed is ALDH1A1; the disease is pancreatic neoplasm.